Albion Financial Group UT bought a new stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,757 shares of the exchange traded fund’s stock, valued at approximately $158,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tidemark LLC increased its holdings in SPDR S&P Biotech ETF by 101.5% during the 3rd quarter. Tidemark LLC now owns 395 shares of the exchange traded fund’s stock worth $39,000 after acquiring an additional 199 shares during the period. Quintet Private Bank Europe S.A. bought a new position in shares of SPDR S&P Biotech ETF in the third quarter worth $40,000. ORG Wealth Partners LLC purchased a new stake in shares of SPDR S&P Biotech ETF in the third quarter worth $44,000. Howe & Rusling Inc. bought a new stake in SPDR S&P Biotech ETF during the third quarter valued at $49,000. Finally, Waldron Private Wealth LLC purchased a new position in SPDR S&P Biotech ETF during the third quarter worth about $54,000.
SPDR S&P Biotech ETF Price Performance
Shares of SPDR S&P Biotech ETF stock opened at $90.51 on Wednesday. SPDR S&P Biotech ETF has a 1 year low of $81.14 and a 1 year high of $105.47. The firm has a market cap of $6.90 billion, a PE ratio of 11.47 and a beta of 1.11. The company has a 50 day simple moving average of $93.58 and a two-hundred day simple moving average of $96.95.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- Top Biotech Stocks: Exploring Innovation Opportunities
- Rivian: Weathering the Storm, Poised for Growth?
- What is the Dow Jones Industrial Average (DJIA)?
- Avient Stock: Manufacturing Play With Double-Digit Upside
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.